Literature DB >> 27988141

Filgotinib for Crohn's disease-expanding treatment options.

Ashwin N Ananthakrishnan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27988141     DOI： 10.1016/S0140-6736(16)32538-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

2.  Targeting Remission in Moderate-to-Severe Crohn's Disease.

Authors:  Troy Kish
Journal:  P T       Date:  2018-06

Review 3.  Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment.

Authors:  Moses M Kasembeli; Uddalak Bharadwaj; Prema Robinson; David J Tweardy
Journal:  Int J Mol Sci       Date:  2018-08-05       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.